Stockreport

Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024 [Yahoo! Finance]

Lumos Pharma, Inc.  (LUMO) 
PDF for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two po [Read more]